EcoDrugPlus

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSMSIG00000019058
Gene Symbol: PPARA
1 Cross references
468 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Gamma

Ensembl ID : ENSMSIG00000031935
Gene Symbol: PPARG
1 Cross references
420 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSMSIG00000014858
Gene Symbol: PIK3CB
1 Cross references
230 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSMSIG00000013088
Gene Symbol: PIK3CD
1 Cross references
228 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSMSIG00000004551
Gene Symbol: PIK3CG
1 Cross references
228 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSMSIG00000013595
Gene Symbol: PDE10A
1 Cross references
220 Possible Orthologues:

Phosphodiesterase 3a, Cgmp Inhibited

Ensembl ID : ENSMSIG00000019105
Gene Symbol: PDE3A
1 Cross references
287 Possible Orthologues:

Phosphodiesterase 3b, Cgmp-Inhibited

Ensembl ID : ENSMSIG00000028820
Gene Symbol: PDE3B
1 Cross references
232 Possible Orthologues:

Phosphodiesterase 4a, Camp Specific

Ensembl ID : ENSMSIG00000016751
Gene Symbol: PDE4A
1 Cross references
290 Possible Orthologues:

Phosphodiesterase 4b, Camp Specific

Ensembl ID : ENSMSIG00000010360
Gene Symbol: PDE4B
1 Cross references
310 Possible Orthologues:

Phosphodiesterase 4c, Camp Specific

Ensembl ID : ENSMSIG00000032074
Gene Symbol: PDE4C
1 Cross references
284 Possible Orthologues:

Phosphodiesterase 4d, Camp Specific

Ensembl ID : ENSMSIG00000016032
Gene Symbol: PDE4D
1 Cross references
259 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).